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Veterinary use of the non-steroidal anti-inflammatory 
drug, diclofenac is responsible for the population col-
lapse of resident vulture species in India. Conservation 
efforts, including a ban on veterinary diclofenac and 
the identification of a vulture-safe alternative (meloxi-
cam), were introduced in 2006 in order to address the 
threat. Sampling of domesticated ungulate carcasses 
available to vultures in India was undertaken in three 
surveys prior to, around the time of, and 1–2 years  
after the ban in order to quantify the prevalence of  
diclofenac and meloxicam residues. A total of 1445, 
1488 and 1251 liver tissue samples were collected from 
nine states and analysed with a validated LC-ESI/MS 
methodology. Overall diclofenac prevalence levels de-
clined by almost a half over the three surveys, and 
there was an increase in meloxicam prevalence  
between the second and third surveys, although some 
states revealed little change. These surveys indicate 
that two of the key conservation actions to counter the 
threat faced by vultures – banning veterinary diclofenac 
and promoting meloxicam as a safe alternative – are 
beginning to take effect. However, because only a small 
proportion of diclofenac-contaminated carcasses is 
sufficient to cause vulture population declines, further 
efforts are needed to eliminate diclofenac from the 
food supply of India’s vultures. 
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VULTURE populations in India have undergone a catas-
trophic collapse since the early 1990s with three resident 
species, the Oriental white-backed vulture (Gyps bengalen-
sis), long-billed vulture (G. indicus) and slender-billed 
vulture (G. tenuirostris), which together used to number 
tens of millions, now listed by the International Union for 
the Conservation of Nature (IUCN) as Critically Endan-
gered1. Population decreases were first recorded to have 
started for the Oriental white-backed vulture between 
1987 and 1996 at the Keoladeo National Park2, and  
nationwide road-transect surveys showed that vultures 
had decreased across India between 1992 and 2000 (ref. 
3). By 2007, the number of Oriental white-backed vultures 
had decreased by 99.9% in comparison to the early 
1990s, with the long-billed vulture and slender-billed vul-
ture decreasing by > 98% over the same period4. An  
intensive research programme undertaken in India, Paki-
stan and Nepal has shown that veterinary use of the non-
steroidal anti-inflammatory drug (NSAID), diclofenac is 
the main and perhaps the only cause of the population  
decline5–9. Vultures are exposed to diclofenac when they 
feed from carcasses of livestock that have died within a 
few days of treatment and so contain residues of the 
drug6. Birds that consume sufficient tissues from such 
carcasses die from kidney failure 1–2 days after expo-
sure6,10. Population modelling has shown that just 0.8% 
of ungulate carcasses available to vultures would need to 
contain a lethal dose of diclofenac to cause the observed 
population declines5. However, surveys of ungulate car-
casses collected from across northern India in 2004–2005 
and 2006 revealed that 10–11% of carcasses contained 
detectable levels of diclofenac residues11,12. The preva-
lence and concentration of diclofenac in these carcasses 
was more than sufficient to account for the rapid vulture 
population declines13. 
 In response to the threat faced by vultures, the Drug 
Controller General of India wrote to all State Drug Con-
trollers in May 2006 withdrawing the licence to manufac-
ture veterinary forms of diclofenac. This 2006 directive 
was strengthened in 2008 to make it an imprisonable  
offence to manufacture, retail or use diclofenac for veteri-
nary purposes. To help address the problem being caused 
by diclofenac, researchers have now tested two other 
NSAIDs in an effort to identify alternatives to find other 
drugs that are both of low toxicity to vultures and also  
effective for treating livestock. This work, undertaken in 
India and southern Africa, revealed that the veterinary 
NSAID, meloxicam is of low toxicity to vultures and 
other scavenging birds14–16, but that ketoprofen causes the 
same toxic effects as diclofenac in vultures17, though for-
tunately its prevalence in ungulate carcasses in India is 
low12. Consequently, meloxicam has been promoted in 
India in an effort to replace veterinary use of diclofenac 
with this safe alternative18. However, ketoprofen is still 
licensed for veterinary use. 
 In this communication, we report the prevalence of 
veterinary NSAIDs in carcasses of domesticated ungulates 
sampled across northern and central India during the period 
January 2007 to December 2008, 1–2 years after the diclo-
fenac ban and after the promotion of meloxicam. The re-
sults are compared with earlier pre-ban and immediately 
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Table 1. Number of ungulate liver samples collected, the prevalence (% of samples) of detectable diclofenac residues in three surveys and the 
prevalence of meloxicam residues in two surveys, for nine states where repeat sampling occurred. In addition, total number of samples and overall 
prevalence are given for the entire dataset and for a sub-set of seven site-clusters (see text) sampled in all three surveys, adjusted for sampling  
 effort in each cluster 
 Carcass samples (n) Diclofenac (%) Meloxicam (%) 
 
Location S1 S2 S3 S1 S2 S3 S1 S2 S3 
 
Andhra Pradesh 154 – 143 2.6 – 1.4 – – 0.7 
Gujarat 65 222 159 9.2 4.1 1.9 – 0.0 4.4 
Jammu and Kashmir 77 112 – 3.9 3.6 – – 11.6 – 
Madhya Pradesh 195 236 257 11.3 12.7 3.9 – 0.8 7.0 
Maharashtra 194 241 262 5.7 11.2 5.3 – 4.6 7.3 
Punjab 76 228 – 15.8 12.3 – – 7.5 – 
Rajasthan 310 339 303 17.1 14.5 12.2 – 4.7 5.9 
Uttar Pradesh 280 – 127 11.8 – 3.1 – – 3.1 
West Bengal 94 110 – 9.6 16.4 – – 0.9 – 
All states 1445 1488 1251 10.6 11.1 5.6 – 4.0 5.4 
Seven site-clusters (adjusted for effort) 518 728 981 13.5 11.4 8.9 – 3.0 6.0 
 
post-ban data in order to assess the effectiveness of the 
banning of diclofenac and the promotion of meloxicam at 
reducing the threat to India’s vulture populations. 
 Ungulate carcasses were sampled across India during 
three separate survey periods (hereafter referred to as 
Surveys 1–3). States selected for sampling were chosen 
on the basis of being representative of North, West, East 
and Central India, where vulture populations were for-
merly most abundant7. Survey 1 collected 1445 samples 
from 62 sites in nine states between May 2004 and July 
2005, a period 1–2 years prior to the 2006 diclofenac ban. 
Survey 2 collected 1488 samples at 26 sites in seven 
states from May to December 2006, immediately after the 
announcement of the ban in May 2006 (at which point, a 
three-month period was given in order to implement the 
directive). Survey 3 collected 1251 samples from 15 sites 
in six states between January 2007 and December 2008. 
The coverage of states varied among surveys (Table 1). 
Samples were collected from carcass dumps managed by 
local government municipalities, co-operative and private 
companies, or from animal welfare charities and village 
carcass dumps. More than 99% of the samples were col-
lected from carcass dumps, with a small number of addi-
tional samples (< 0.5%) collected opportunistically from 
carcasses encountered along roads and in fields. Previous 
publications11,13,19 analysed 1848 samples collected from 
67 sites and 12 states in Survey 1, a total that includes 
279 samples collected from slaughterhouses in three 
states, and 121 and 3 samples from carcass dumps in Bihar 
and Jharkhand respectively. Neither Bihar and Jharkhand 
states were sampled, nor were the slaughterhouses visited 
in Surveys 2 or 3, and, these 403 samples were excluded 
from our analyses. Consequently, in this communication, 
changes in the prevalence of diclofenac in ungulate car-
casses are only reported for samples collected at carcass 
dumps and for the nine states that were sampled on two 
or more occasions in the three surveys (Table 1). 
 Carcass dumps sampled within each state were those 
where access and permission to collect was obtained 
readily. Hence, these sites might not be a random sample 
of locations where ungulate carcasses were available to 
vultures. Where possible, samples were collected from 
the same carcass dump as for the previous surveys. 
Where this was no longer possible, samples were col-
lected from the next nearest available site. The location 
of all dumps in all three surveys was recorded with a 
handheld GPS. At each site, liver samples were collected 
from all ungulate carcasses that were delivered to the 
dump on the day of sampling, thereby providing a repre-
sentative sample of carcasses at the site on that day with 
no possible bias with regard to species, age or sex. At one 
site in Survey 1, the large number of animals arriving 
prevented all carcasses from being sampled, and only 
young, prime and mature animals were sampled19, with 
infant, immature and old animals being excluded. Detailed 
protocols on the location of carcass dumps and collection 
of carcass samples have been reported elsewhere19. For 
each carcass, approximately 2 g of liver tissue was col-
lected, immediately frozen and kept frozen during trans-
portation to the laboratory for analysis19. Majority of 
carcasses (94–95%) were of cattle or buffalo, with occa-
sional samples from sheep, goats, horses and camels. 
 In the laboratory, a sub-sample of each liver tissue was 
removed and weighed to between 0.45 to 0.55 g (to 
± 0.0001 g). Each sub-sample was placed in a fresh glass 
test tube and homogenized with 2 ml of HPLC-grade 
Acetonitrile (Merck) using an Ultra Turrax IKA T8 homo-
genizer. The homogenate was centrifuged at 1000 g, then 
filtered through a 0.45 μm Nylon filter into a 2 ml LCMS 
vial and stored at –20°C until analysis. Analysis of diclo-
fenac and meloxicam residues was undertaken with a vali-
dated liquid chromatography–electrospray ionization mass 
spectrometry (LC–ESI/MS) approach11,12. The analytical 
procedure is reported in detail elsewhere11,12, and the same 
methods were followed in the present study. Values for 
meloxicam were only quantified in Surveys 2 and 3, fol-
lowing the development of a multi-NSAID methodology12. 
The limit of quantification for the LC–ESI/MS technique 
RESEARCH COMMUNICATIONS 
 
CURRENT SCIENCE, VOL. 101, NO. 11, 10 DECEMBER 2011 1482 
(back-calculated in wet tissue concentration) for diclofenac 
and meloxicam was 0.01 ppm (0.01 mg kg–1)12. 
 We report the prevalence of detectable diclofenac and 
meloxicam residues over the whole period of each survey 
and separately by states. It is known from previous analy-
ses that the prevalence varied geographically11, so spuri-
ous differences among surveys in average prevalence 
might arise as a consequence of differences in the distri-
bution of sampling. In order to avoid this potential bias 
all sampling locations were attributed to a site-cluster, 
with all sampling sites located within a 186 km radius of 
the geodesic centroid of the site-cluster. In Survey 3, all 
sampling sites could be attributed to the same 21 site-
clusters as those for Surveys 1 and 2. Samples were  
obtained in all three surveys for seven site-clusters, with 
a further five site-clusters sampled in Surveys 1 and 2 
only, and two site-clusters sampled in Surveys 1 and 3 
only (Figure 1). To allow for potential effects caused by 
differences in the distribution of sampling, we estimated 
change in the prevalence of diclofenac using only the 
data for the seven site-clusters sampled in all three sur-
veys, which were located in Gujarat (n = 2 clusters), Ra-
jasthan (n = 2), Madhya Pradesh (n = 2) and Maharashtra 
(n = 1; Figure 1). For each survey, we calculated the 
negative cumulative distribution of diclofenac values for 
these seven site-clusters. We allowed for differences 
among surveys in the proportion of samples obtained at 
each of these seven site-clusters. We did this by assigning 
a weight ni1/(nijN1) to each sample value, where ni1 is the 
number of samples obtained in Survey 1 at the ith site-
cluster, nij is the number of samples obtained in the jth 
survey at the ith site-cluster and N1 is the total number of 
samples obtained at all seven site-clusters sampled in all  
 
 
 
 
 
Figure 1. Map of the Indian subcontinent showing the location of 
centroids for the 21 site-clusters at which carcass sampling was under-
taken. The seven site-clusters where samples were collected in all three 
surveys are indicated by filled triangles; squares indicate sites surveyed 
in Surveys 1 and 2 only; crosses indicate sites surveyed in Surveys 1 
and 3 only, and circles show sites surveyed in Survey 1 only. 
surveys. The negative cumulative distribution of diclo-
fenac and meloxicam values was then obtained by accu-
mulating these weighted values from each of the surveys 
in ascending order and then subtracting the result from 
one. This calculation produces negative cumulative dis-
tributions for Surveys 2 and 3, which simulate the  
expected distributions if the same proportions of samples 
had been taken in the seven site-clusters in Surveys 2 and 
3 as were taken in these site-clusters in Survey 1. Statistical 
analysis on the significance of changes in the prevalence 
of diclofenac and meloxicam residues was undertaken 
through logistic regression, with the presence or absence 
of detectable drug residues as the binary dependent vari-
able, survey as a factor with three levels (one each for 
Surveys 1–3) and state as a factor with nine or four levels 
(see below) as independent variables, and with a two-way 
interaction between these two factors. This is termed the 
full model. Simplified models in which the interaction 
term or the main effects were deleted were also fitted and 
likelihood ratio tests used to test whether these deletions 
resulted in a significant increase in residual deviance. The 
model with no effect of either of the explanatory factors 
is termed the null model. For diclofenac prevalence the 
first analysis used all available data from the nine states 
and three surveys, with a second analysis undertaken on 
the restricted set of data from the seven site-clusters and 
four states that were sampled in all three surveys. The 
same two analyses were undertaken for meloxicam, but 
only utilizing data from Surveys 2 and 3. 
 A total of 1445, 1488 and 1251 liver tissue samples 
were analysed from Surveys 1–3 respectively (Table 1). 
For diclofenac prevalence and using the dataset of all 
states, the full logistic regression model indicated that the 
survey factor, the state factor and their two-way interac-
tion combined reduced the residual deviance to a highly 
significant extent when compared with the null model 
(difference in deviance between the full model and the 
null model = 135.8, difference in degrees of free-
dom = 21, P < 0.0001). Deletion of the two-way interac-
tion term from the model caused no significant increase 
in residual deviance (difference in deviance = 19.1, dif-
ference in df = 11, P = 0.059), whereas deletion of either 
state or survey as a factor resulted in a highly significant 
increase in deviance (P < 0.0001 for both factors). We 
therefore concluded that the model with both survey and 
state included as main effects was the minimal adequate 
model of diclofenac prevalence for all states. The equiva-
lent logistic regression analysis on diclofenac prevalence 
within the restricted set of seven site-clusters surveyed in 
all three surveys indicated a similar pattern to the analy-
sis of data for all states. The full model reduced residual 
deviance to a highly significant extent when compared 
with the null model (difference in deviance = 76.6, dif-
ference in degrees of freedom = 11, P < 0.0001). How-
ever, deletion of the two-way interaction term from the 
model caused no significant increase in residual deviance 
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(difference in deviance = 9.3, difference in df = 6, P = 0.16) 
and the best-fit model was one with both survey and state 
being included as the main effects. Overall, the preva-
lence of diclofenac decreased markedly in Survey 3 in 
comparison with the first two surveys, with a similar pat-
tern of change over time in the seven site-clusters as in 
the data from all states (Table 1, Figure 2 a). Diclofenac 
prevalence in Surveys 1–3 from the seven site-clusters 
was 13.5%, 11.4% and 8.9% respectively. These preva-
lence levels are higher than those indicated for all states 
that were sampled, as Rajasthan has a high diclofenac 
prevalence in comparison to the other states (Table 1) and 
a high proportion of samples (43%) were collected from 
this state. As well as indicating a decrease in diclofenac 
prevalence, the seven site-clusters data indicate a drop in 
the median value of concentration in those samples for 
which diclofenac was detected (Figure 2 a). State figures 
for diclofenac indicate a high degree of variation in  
diclofenac prevalence among the states (Figure 3 a). 
 
 
 
Figure 2. Negative cumulative distribution of diclofenac concentra-
tions (a) and meloxicam concentration (b) for samples collected from 
the seven site-clusters subset in Survey 1 (black line), Survey 2 (red line) 
and Survey 3 (green line), indicating the overall decrease in diclofenac 
prevalence over the period covered by the three surveys (13.5%, 11.4% 
and 8.9% respectively), and the increase in meloxicam prevalence (3.0 
and 6.0% respectively). Median values of diclofenac and meloxicam in 
the three surveys are indicated by the vertical dashed lines. 
 For the meloxicam data there was significant reduction 
in residual deviance for the full model versus the null 
model for both the complete dataset from Surveys 2 and 3 
(difference in deviance between the full model and the 
null model = 65.8, difference in degrees of freedom = 12, 
P < 0.0001) and the restricted seven site-clusters dataset 
(difference in deviance = 38.7, difference in degrees of 
freedom = 11, P < 0.0001). Deletion of the two-way inter-
action term from the model caused a significant increase 
in residual deviance for both the full dataset (difference 
in deviance = 14.7, difference in degrees of freedom = 3, 
P < 0.01) and the restricted seven site-clusters dataset 
(difference in deviance = 15.7, difference in degrees of 
freedom = 7, P < 0.05). We therefore conclude that for 
both datasets the full model with survey, state and their 
two-way interaction is the minimal adequate model of 
meloxicam prevalence. In the seven site-clusters, preva-
lence of meloxicam in carcass samples doubled from 
3.0% to 6.0% from Surveys 2 to 3 (Table 1; Figure 2 b), 
along with an increase in the median value of positive 
samples (Figure 2 b). Prevalence figures for all four states 
sampled in Surveys 2 and 3 indicated an increase in 
meloxicam usage, and with Gujarat and Madhya Pradesh 
showing greater increase in comparison to Maharashtra 
and Rajasthan (Figure 3 b). 
 The changing patterns of diclofenac and meloxicam 
prevalence recorded by the three surveys analysed here 
indicate that there have been significant changes in  
veterinary use of these two NSAIDs in India since the  
 
 
 
 
Figure 3. Proportion of samples positive for diclofenac (a) and 
meloxicam (b) in nine states (Andhra Pradesh, Gujarat, Jammu & 
Kashmir, Madhya Pradesh, Maharashtra, Rajasthan, Uttar Pradesh and 
West Bengal) from Survey 1 (black squares), Survey 2 (red squares) 
and Survey 3 (green squares). Vertical lines indicate the 95% binomial 
confidence limits around the proportion. Meloxicam residues were only 
analysed in Surveys 2 and 3. 
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ban on veterinary use of diclofenac in 2006. The direction 
of the changes, with an overall decrease in diclofenac 
prevalence and increase in meloxicam prevalence, indi-
cates that two of the key conservation actions taken, 
namely the national ban on veterinary use of diclofenac 
and promotion of the vulture-safe alternative, meloxicam 
to counter the threat faced by vultures, are beginning to 
take effect. National figures, based on all nine states that 
were sampled, indicate that the prevalence of diclofenac 
has declined by almost half 1–2 years after the ban, with 
5.6% of samples containing diclofenac in the third survey 
in comparison to 10–11% found prior to and around the 
time of the ban in 2006. Comparison of data from the 
seven site-clusters that were sampled in all three surveys 
and adjusted for sampling effort confirms this pattern of 
decrease, though with a somewhat smaller decrease: at 
these sites the decrease is from 13.5% prior to the ban to 
8.9% after the ban. Values for meloxicam prevalence in-
dicate an opposing trend to that recorded for diclofenac, 
with a doubling in the proportion of carcass samples with 
residues of this drug from Survey 2 to 3. The average 
concentrations of diclofenac and meloxicam also show 
opposite changes over time: the median concentration of 
diclofenac declined, while that of meloxicam increased. 
 Diclofenac is now widely recognized as the main driv-
ing force behind the rapid decline in India’s vulture popu-
lations over recent times6–9, and consequently evidence 
for a decline both in the prevalence and concentration of 
diclofenac residues in ungulate carcasses is important for 
India’s threatened vulture populations. Comprehensive 
modelling20, based on the results of these three surveys 
and the relationship between diclofenac levels and vul-
ture toxicity, suggests that for the Oriental white-backed 
vulture the expected rate of population decline caused by 
diclofenac poisoning has decreased by around a third for 
Survey 3 in comparison to the rate predicted from Survey 
1. This modelling indicates an annual decline rate of 
around 18% (ref. 20). While a reduction in population  
decline rate from 44% to 18% is a marked improvement 
in the rate of decline observed in the wild for Oriental 
white-backed between 2000 and 2007 (ref. 4), it is still a 
rapid rate of decrease. Because a small proportion 
(< 0.8%) of ungulate carcasses containing lethal levels of 
diclofenac is sufficient to cause the observed rapid popu-
lation declines4, efforts to ban diclofenac and replace it 
with meloxicam will have to markedly increase in effec-
tiveness to remove the threat currently faced by India’s 
vulture populations. In the meantime, conservation initia-
tives, including captive breeding and preparation for rein-
troduction to the wild of threatened vultures remain vital 
in order to safeguard these critically endangered species. 
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